Tag: JJs
J&J’s immunology meds Stelara, Tremfya posted big revenue gains, but pricing...
Johnson & Johnson touted solid growth for its immunology meds Stelara and Tremfya in its latest quarterly results, but Bernstein analysts are spotlighting steep net pricing...
J&J’s next-gen Darzalex sparks drug delivery royalties battle
Johnson & Johnson scaled back its Darzalex royalty payments to Genmab in the second quarter, just as its new subcutaneous formulation was hitting the...
